SCHEMBL11907002

SCHEMBL11907002

Cc1cc(-c2[c]c(C(N)=O)ncc2)cc(N)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 1/20 0.41
MKNK2 Q9HBH9 1/20 0.41
PIK3CB P42338 1/20 0.39
DYRK1A Q13627 1/20 0.38
CCNC P24863 2/20 0.37
CDK8 P49336 2/20 0.37
NOS3 P29474 2/20 0.34
NOS1 P29475 2/20 0.34
NOS2 P35228 2/20 0.34
KMT2A Q03164 2/20 0.34
CDC7 O00311 2/20 0.34
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
BTK Q06187 1/20 0.33
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRB1 P18505 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11909659 0.83 MKNK1 (0.39) MKNK1MKNK2NOS3NOS1NOS2
SCHEMBL11907716 0.83 MKNK1 (0.39) MKNK1MKNK2DYRK1ANOS3NOS1
SCHEMBL11909040 0.78 HSP90AA1 (0.40) MKNK2PIK3CBCDC7DBF4IRAK4
SCHEMBL11908324 0.78 PIK3CA (0.36) MKNK1MKNK2PIK3CBNOS3NOS1
SCHEMBL11908092 0.75 MKNK1 (0.33) MKNK1MKNK2KMT2AMEN1GABRP
SCHEMBL18554602 0.73 CDC7 (0.40) MKNK1MKNK2CDC7BTKPOLB
SCHEMBL11906940 0.73 NOS3 (0.35) MKNK1MKNK2DYRK1ANOS3NOS1
SCHEMBL3177261 0.71 MAP4K4 (0.47) MKNK1MKNK2
SCHEMBL4950838 0.71 PIM1 (0.40) MKNK1MKNK2CDK8KMT2ACDC7
SCHEMBL11907122 0.70 NOS3 (0.35) MKNK1MKNK2PIK3CBNOS3NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140249135-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2014-09-04 US disclosed
US-8822497-B2 PIM kinase inhibitors and methods of their use NOVARTIS AG (CH) 2014-09-02 US disclosed
EP-2132177-B1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2013-07-17 EP disclosed
US-20120208815-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2012-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140249135-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE PIM1, PIM2, PIM3 MKNK1 149/4885MKNK2 215/4885PIK3CB 277/4885
US-20120208815-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE PIM1, PIM2, PIM3 MKNK1 149/4885MKNK2 215/4885PIK3CB 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.